Psychedelic Drug Trials: Are Your Sites Ready?

Momentum around psychedelic drug development is accelerating, but these studies introduce operational challenges that many traditional CNS sites are not prepared to manage.

In this brief article, we explore four factors that sponsors should consider when evaluating sites:

• Endpoint complexity and specialized assessments
• Structural blinding during treatment sessions
• Patient vulnerability and psychological risk
• Set and setting as part of study execution

As psychedelic programs advance, site readiness will be critical to protecting patient safety, trial quality, and data integrity.

Download the article to explore the four key operational challenges.